I already had good results with scafols, now I intend to include drugs in my experiments.
Nihon Hinyokika Gakkai Zasshi. 2013 Nov;104(6):681-7.
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
[Article in Japanese]
Takayama T, Sugiyama T, Furuse H, Yajima T, Suzuki T, Kai F, Nagata M, Otsuka A, Ishii Y2, Ozono S.
email: [email protected]
Abstract
OBJECTIVES:
To evaluate the treatment for castration-refractory prostate cancer (CRPC) resistant to docetaxel
MATERIALS AND METHODS:
Among 45 patients with CRPC treated with docetaxel (70-75 mg/m2) every 3 to 4 weeks at Hamamatsu University Hospital from January 2004 to July 2012, 19 patients underwent salvage treatments. We retrospectively analyzed the medical records of 14 patients except for 5 patients who were enrolled in clinical trials.
RESULTS:
The median age and serum prostate-specific antigen (PSA) level at starting salvage treatments was 71 years (range 45 to 79) and 241.1 ng/mL (range 3.06 to 1,643.0), respectively. All patients maintained castration status. Salvage treatments include DTX (30 mg/m2) + cisplatin (CDDP) (70 mg/m2)/carboplatin (Area under the curve = 4), etoposide + CDDP, paclitaxel + CDDP, cyclophosphamide, S-l, tegaful-uracil. The reasons why 14 patients moved to salvage treatments after DTX were progressive disease in 12 patients and adverse events in 2. Eight patients had a PSA response, 3 patients>50% and 5 patients
- Badges
- Science topic
- Similar topics
- Control Systems Engineering
- Filtering